A reappraisal of inspiratory capacity in chronic obstructive pulmonary disease: clinical correlates and role of long-acting muscarinic antagonists and long-acting β2 agonists

References

• Hutchinson J. On the capacity of the lungs, and on the respiratory functions, with a view of establishing a precise and easy method of detecting disease by the spirometer. Med Chir Trans (London). 1846;29(1):137–161.
   PubMedGoogle Scholar
• Petty TL. COPD in perspective. Chest. 2002;121(5 Suppl):116S–120S.
   PubMedGoogle Scholar
• Tiffeneau R, Pinelli AF. Air circulant et air captif dans l’exploration de la fonction ventilatrice pulmonaire [circulating air and captive air in the exploration of the pulmonary ventilator function]. Paris Med. 1947;133:624–628.
   Google Scholar
• Huang WC, Wu MF, Chen HC, et al. Features of COPD patients by comparing CAT with mMRC: a retrospective, cross-sectional study. NPJ Prim Care Resp Med. 2015;25(1):15063.
   PubMedGoogle Scholar
• Milic-Emili J. Inspiratory capacity and exercise tolerance in chronic obstructive pulmonary disease. Can Respir J. 2000;7(3):282–285.
   PubMedGoogle Scholar
• Milic-Emili J. Dynamic pulmonary hyperinflation and intrinsic PEEP: consequences and management in patients with chronic obstructive pulmonary disease. Recenti Prog Med. 1990;81(11):733–737.
   PubMedGoogle Scholar
• Di Marco F, Sotgiu G, Santus P, et al. Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis. Respir Res. 2018;19(1):18.
   PubMedGoogle Scholar
• Shore SA, Milic-Emili J, Martin JG. Reassessment of body plethysmographic technique for the measurement of thoracic gas volume in asthmatics. Am Rev Respir Dis. 1982;126(3):515–520.
   PubMedGoogle Scholar
• Santus P, Radovanovic D, Henchi S, et al. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir Physiol Neurobiol. 2014;197:36–45.
   PubMed Web of Science ®Google Scholar
• Tantucci C, Duguet A, Similowski T, et al., Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J. 12(4): 799–804. 1998.
   PubMed Web of Science ®Google Scholar
• Freedman S. Lung volumes. Br J Clin Pharmacol. 1979;8(2):99–107.
   PubMedGoogle Scholar
• Lutfi MF. The physiological basis and clinical significance of lung volume measurements. Multidiscip Respir Med. 2017;12(3). https://doi.org/10.1186/s40248-017-0084-5
   Google Scholar
• Hallett S, Toro F, Ashurst JV. Physiology, tidal volume StatPearls. [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482502/
   Google Scholar
• Lofrese JJ, Tupper C, Lappin SLP. 2021. Residual volume. [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK493170/
   Google Scholar
• Haddad M, Sharma S. Physiology, lung. in: statpearls [ Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545177/
   Google Scholar
• David S, Sharma S. Vital capacity.[Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK541099/
   Google Scholar
• Delgado BJ, Bajaj T. Physiology lung capacity. [Internet]. Treasure Island (FL): StatPearls Publishing, Available from: https://www.ncbi.nlm.nih.gov/books/NBK541029/
   Google Scholar
• Milic-Emili J, Marazzini L, D’Angelo E. 150 years of blowing: since John hutchinson. Can Respir J. 1997;4(5):321329.
   Google Scholar
• Cid-Juàrez S, Thirión-Romero I, Torre-Bouscoulet L, et al. Inspiratory capacity and vital capacity of healthy subjects 9–81 years of age at moderate-high altitude. Respir Care. 2019;64(2):153–160.
   PubMedGoogle Scholar
• Zilianti C, Santus P, Pecchiari M, et al. Diagnostic insights from plethysmographic alveolar pressure assessed during spontaneous breathing in COPD patients. Diagnostics (Basel). 2021;11(6):918.
   PubMedGoogle Scholar
• O’Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(5):770–777.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Milne KM, James MD, et al. Dyspnea in COPD: new mechanistic insights and management implications. Adv Ther. 2020;37(1):41–60.
   PubMed Web of Science ®Google Scholar
• Decramer M. Respiratory muscle interaction during acute and chronic hyperinflation. Monaldi Arch Chest Dis. 1993;48(5):483–488.
   PubMedGoogle Scholar
• Soffler MI, Hayes MM, Schwartzstein RM. Respiratory sensations in dynamic hyperinflation: physiological and clinical applications. Respir Care. 2017;62(9):1212–1223.
   PubMed Web of Science ®Google Scholar
• Leith DE, Brown R. Human lung volumes and the mechanisms that set them. Eur Respir J. 1999;13(2):468–472.
   PubMedGoogle Scholar
• O’Donnell DE, Laveneziana P. Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev. 2006;15(100):61–67.
   Google Scholar
• O’Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD. 2007;4(3):225–236.
   PubMedGoogle Scholar
• O’Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(2):180–184.
   PubMedGoogle Scholar
• James MD, Milne KM, Phillips DB, et al. Dyspnea and exercise limitation in mild COPD: the value of CPET. Front Med (Lausanne). 2020;7:442.
   PubMedGoogle Scholar
• MacNee W. Pathophysiology of acute exacerbations of chronic obstructive pulmonary disease. In: Siafakas NM, Anthonisen NR, Georgopoulos D, editors. Acute exacerbations of chronic obstructive pulmonary disease. lung biology in health and disease. New York (NY): Marcel Dekker; 2004. p. 29.
   Google Scholar
• Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343(4):269–280.
   PubMed Web of Science ®Google Scholar
• Ferguson GT. Why does the lung hyperinflate? Proc Am Thorac Soc. 2006;3(2):176–179.
   PubMedGoogle Scholar
• Stubbing DG, Pengelly LD, Morse JL, et al. Pulmonary mechanics during exercise in subjects with chronic airflow obstruction. J Appl Physiol Respir Environ Exerc Physiol. 1980;49(3):511–515.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(5):1557–1565.
   PubMed Web of Science ®Google Scholar
• De Weger WW, Klooster K, Ten Hacken NH, et al. Determining static hyperinflation in patients with severe emphysema: relation between lung function parameters and patient‑related outcomes. Lung. 2020;198(4):629–636.
   PubMedGoogle Scholar
• Rodenstein DO, Francis C, Stănescu DC. Airway closure in humans does not result in overestimation of plethysmographic lung volume. J Appl Physiol Respir Environ Exerc Physiol. 1983;55(6):1784–1789.
   PubMedGoogle Scholar
• Shore SA, Huk O, Mannix S, et al. Effect of panting frequency on the plethysmographic determination of thoracic gas volume in chronic obstructive pulmonary disease 1– 3. Am Rev Respir Dis. 1983;1281(1):54–59.
   Google Scholar
• O’Donnell CR, Bankier AA, Stiebellehner L, et al. Comparison of plethysmographic and helium dilution lung volumes. Which is best for COPD? Chest. 2010;1375(5):1108–1115.
   Google Scholar
• Radovanovic D, Pecchiari M, Pirracchio F, et al. Plethysmographic loops: a window on the lung pathophysiology of COPD patients. Front Physiol. 2018;9:484.
   PubMedGoogle Scholar
• Barros CF, Felisberto RM, Nucci KCA, et al. Dynamic hyperinflation induced by the 6- minute pegboard and ring test in hospitalized patients with exacerbated COPD. PloS ONE. 2020;15(11):e0241639.
   PubMedGoogle Scholar
• Meys R, Schiefer M, de Nijs SB, et al. Measurement of dynamic hyperinflation during the 6-minute walk test using a mobile device. Respir Care. 2019;64(2):182–188.
   PubMedGoogle Scholar
• Luo YM, Qiu ZH, Wang Y, et al. Absence of dynamic hyperinflation during exhaustive exercise in severe COPD reflects submaximal IC maneuvers rather than a nonhyperinflator phenotype. J Appl Physiol. 2020;128(3):586–595.
   PubMedGoogle Scholar
• Santus P, Radovanovic D, Pecchiari M, et al. The relevance of targeting treatment to small airways in asthma and COPD. Respir Care. 2020;65(9):1392–1412.
   PubMedGoogle Scholar
• Celli BR, Decramer M, Lystig T, et al. Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respir Res. 2012;13(1):66.
   PubMedGoogle Scholar
• French A, Balfe D, Mirocha JM, et al. The inspiratory capacity/total lung capacity ratio as a predictor of survival in an emphysematous phenotype of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1305–1312.
   PubMed Web of Science ®Google Scholar
• Casanova C, Cote C, de Torres JP, et al., Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 171(6): 591–597. 2005.
   PubMed Web of Science ®Google Scholar
• Berry C, Wise RA. Mortality in COPD: causes, risk factors, and prevention. COPD. 2010;7(5):375–382.
   PubMedGoogle Scholar
• Yetkin O, Gunen H. Inspiratory capacity and forced expiratory volume in the first second in exacerbation of chronic obstructive pulmonary disease. Clin Respir J. 2008;2(1):36–40.
   PubMedGoogle Scholar
• Cardoso J, Coelho R, Rocha C, et al. Prediction of severe exacerbations and mortality in COPD: the role of exacerbation history and inspiratory capacity/total lung capacity ratio. Int J Chron Obstruct Pulmon Dis. 2018;13:1105–1113.
   PubMed Web of Science ®Google Scholar
• Jo YS, Kim SK, Park SJ, et al. Longitudinal change of FEV1 and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD. J Chron Obstruct Pulmon Dis. 2019; 14: 361–369.
   Google Scholar
• Santus P, Pecchiari M, Tursi F, et al. The airways’ mechanical stress in lung disease: implications for COPD pathophysiology and treatment evaluation. Can Respir J. 2019;2019:3546056.
   PubMedGoogle Scholar
• Ruppel GL. What is the clinical value of lung volumes? Respir Care. 2012;57(1):26–35.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with “irreversible” emphysema. Eur Respir J. 2001;18(6):914–920.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(2):542–549.
   PubMed Web of Science ®Google Scholar
• Cui L, Ji X, Xie M, et al. Role of inspiratory capacity on dyspnea evaluation in COPD with or without emphysematous lesions: a pilot study. J Chron Obstruct Pulmon Dis. 2017; 12: 2823–2830.
   Google Scholar
• Ubolnuar N, Tantisuwat A, Thaveeratitham P, et al. Effects of pursed-lip breathing and forward trunk lean postures on total and compartmental lung volumes and ventilation in patients with mild to moderate chronic obstructive pulmonary disease. An obs study Med. 2020;99. 51.
   Google Scholar
• Santus P, Bassi L, Radovanovic D, et al. Pulmonary rehabilitation in COPD: a reappraisal 2008-2012. Pulm Med. 2013;2013:374283.
   PubMedGoogle Scholar
• Santus P, Radovanovic D, Balzano G, et al. Improvements in lung diffusion capacity following pulmonary rehabilitation in COPD with and without ventilation inhomogeneity. Respiration. 2016;925(5):295–307.
   Google Scholar
• Visser FJ, Ramlal S, Dekhuijzen PN, et al. Pursed-lips breathing improves inspiratory capacity in chronic obstructive pulmonary disease. Respiration. 2011;81(5):372–378.
   PubMedGoogle Scholar
• Varol Y, Şahin H, Aktürk Ü, et al. Effect of pulmonary rehabilitation on the value of the inspiratory capacity-to-total lung capacity (IC/TLC) ratio to determine response to pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. Turk Thorac J. 2019;20(4):224–229.
   PubMedGoogle Scholar
• Radovanovic D, Contoli M, Marco FD, et al. Clinical and functional characteristics of COPD patients across GOLD classifications: results of a multicenter observational study. COPD. 2019;16(3–4):215–226.
   PubMedGoogle Scholar
• Zhang Y, Sun XG, Yang WL, et al. Inspiratory fraction correlates with exercise capacity in patients with stable moderate to severe COPD. Respir Care. 2013;58(11):1923–1930.
   PubMed Web of Science ®Google Scholar
• D’Angelo E, Radovanovic D, Barbini P, et al. Plethysmographic assessment of tidal expiratory flow limitation. Respir Physiol Neurobiol. 2021;296:103801.
   PubMedGoogle Scholar
• Pecchiari M, Radovanovic D, Zilianti C, et al. Tidal expiratory flow limitation induces expiratory looping of the alveolar pressure-flow relation in COPD patients. J Appl Physiol. 1985;129(1):75–83.
   Google Scholar
• Diaz O, Villafranca C, Ghezzo H, et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J. 2000;16(2):269–275.
   PubMed Web of Science ®Google Scholar
• Albuquerque ALP, Nery LE, Villaça DS, et al. Inspiratory fraction and exercise impairment in COPD patients GOLD stages II–III. Eur Respir J. 2006;28(5):939–944.
   PubMed Web of Science ®Google Scholar
• De Freitas CG, Pereira CA, Viegas CA. Inspiratory capacity, exercise limitation, markers of severity, and prognostic factors in chronic obstructive pulmonary disease. J Bras Pneumol. 2007;33(4):389–396.
   PubMedGoogle Scholar
• Bernard S, LeBlanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(2):629–634.
   PubMed Web of Science ®Google Scholar
• Cabollero P, Zambom-Ferraresi F, Hernández M, et al. Inspiratory fraction as a marker of skeletal muscle dysfunction in patients with COPD. Rev Port Pneumol. 2017;23(1):3–9.
   PubMedGoogle Scholar
• Güder G, Rutten FH. Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence. Curr Heart Fail Rep. 2014;11(3):337–346.
   PubMedGoogle Scholar
• De Souza AS, Sperandio PA, Mazzuco A, et al. Influence of heart failure on resting lung volumes in patients with COPD. J Bras Pneumol. 2016;42(4):273–278.
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD; 2021. www.goldcopd.org
   Google Scholar
• Matera MG, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev. 2020;72(1):218–252.
   PubMed Web of Science ®Google Scholar
• Lal C, Strange C. A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD. Expert Opin Pharmacother. 2017;18(17):1833–1843.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14(1):49.
   PubMedGoogle Scholar
• Calzetta L, Matera MG, Rogliani P, et al. Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. Expert Rev Respir Med. 2018;124(4):261–264.
   Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504.
   PubMed Web of Science ®Google Scholar
• Spina D. Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic? Eur Clin Respir J. 2015;2(1):26634.
   PubMed Web of Science ®Google Scholar
• Pecchiari M, Santus P, Radovanovic D, et al. Acute effects of long-acting bronchodilators on small airways detected in COPD patients by single-breath N2 test and lung P-V curve. J Appl Physiol. 1985;123(5):1266–1275.
   Google Scholar
• Santus P, Radovanovic D, Di Marco S, et al. Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial. Int J Chron Obstruct Pulmon Dis. 2015;10:1917–1923.
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Radovanovic D, Santus P. State of the heart in chronic obstructive pulmonary disease: the best is yet to come. Am J Respir Crit Care Med. 2016;194(11):1433–1434.
   PubMedGoogle Scholar
• Kostikas K, Siafakas NM. Does the term “deflators” reflect more accurately the beneficial effects of long-acting bronchodilators in COPD? COPD. 2016;13(5):537–539.
   PubMedGoogle Scholar
• Magnussen C, Ojeda FM, Rzayeva N, et al. FEV1 and FVC predict all-cause mortality independent of cardiac function. results from the population-based Gutenberg health study. Int J Cardiol. 2017;234:64–68.
   PubMedGoogle Scholar
• Newton MF, O’Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest. 2002;121(4):1042–1050.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Bertley JC, Chau LK, et al. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med. 1997;155(1):109–115.
   PubMed Web of Science ®Google Scholar
• Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124(5):1743–1748.
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15(1):123.
   PubMed Web of Science ®Google Scholar
• Watz H, Troosters T, Beeh KM, et al. ACTIVATE: the effect of Aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2545–2558.
   PubMed Web of Science ®Google Scholar
• Maltais F, Singh S, Donald AC, et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis. 2014;8(6):169–181.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Worsley S, Zhu CQ, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109(7):870–881.
   PubMed Web of Science ®Google Scholar
• Riley JH, Kalberg CJ, Donald A, et al. Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study. ERJ Open Res. 2018;4(1):00073–2017.
   PubMedGoogle Scholar
• Beeh KM, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014;108(4):584–592.
   PubMed Web of Science ®Google Scholar
• Watz H, Mailänder C, Baier M, et al. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study). BMC Pulm Med. 2016;16(1):95.
   PubMedGoogle Scholar
• Andrianopoulos V, Franssen FME, Peeters JPI, et al. Exercise-induced oxygen desaturation in COPD patients without resting hypoxemia. Respir Physiol Neurobiol. 2014;190:40–46.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53–59.
   PubMed Web of Science ®Google Scholar
• O’Donnell D, Casaburi R, De Sousa D, et al. Effects of 6 weeks’ treatment with once-daily tiotropium and olodaterol fixed-dose combination on inspiratory capacity and exercise endurance in patients with COPD: the MoractoTM studies. Am J Respir Crit Care Med. 2015;191:A3972.
   Web of Science ®Google Scholar
• Maltais F, O’Donnell D, Gáldiz Iturri JB, et al. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2018;12:1753465818755091.
   Web of Science ®Google Scholar
• Maltais F, Aumann JL, Kirsten AM, et al. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. Eur Respir J. 2019;53(3):1802049.
   PubMed Web of Science ®Google Scholar
• Maltais F, de la Hoz A, Casaburi R, et al. Effects of tiotropium/olodaterol on activity-related breathlessness, exercise endurance and physical activity in patients with COPD: narrative review with meta-/pooled analyses. Adv Ther. 2021;38(2):835–853.
   PubMedGoogle Scholar
• Troosters T, Maltais F, Leidy N, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(8):1021–1032.
   PubMed Web of Science ®Google Scholar
• Salvi S, Brashier B, Gothi D, et al. Bronchodilator efficacy of tiotropium-formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD. Pulm Pharmacol Ther. 2014;27(1):90–95.
   PubMed Web of Science ®Google Scholar
• Reisner C, Gottschlich G, Fakih F, et al. 24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD. Respir Res. 2017;18(1):157.
   PubMedGoogle Scholar
• De Backer W, De Backer J, Vos W. A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:2673–2684.
   PubMed Web of Science ®Google Scholar
• Usmani OS, Roche N, Jenkins M, et al. Consistent pulmonary drug delivery with whole lung deposition using the aerosphere inhaler: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2021;16:113–124.
   PubMed Web of Science ®Google Scholar
• Lechuga-Ballesteros D, Noga B, Vehring R, et al. Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma. Future Med Chem. 2011;3(13):1703–1718.
   PubMed Web of Science ®Google Scholar
• Vehring R, Lechuga-Ballesteros D, Joshi V, et al. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28(42):15015–15023.
   PubMed Web of Science ®Google Scholar
• Radovanovic D, Mantero M, Sferrazza Papa GF, et al. Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2016;10(10):1045–1055.
   PubMed Web of Science ®Google Scholar
• Wauthoz N, Amighi K. Phospholipids in pulmonary drug delivery. Eur J Lipid Sci Technol. 2014;116(9):1114–1128.
   Web of Science ®Google Scholar
• Taylor G, Warren S, Dwivedi S, et al. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology. Eur J Pharm Sci. 2018;111:450–457.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Webb KA. Breathlessness in patients with severe chronic airflow limitation. Phy corr Chest. 1992;102(3):824–831
   PubMed Web of Science ®Google Scholar
• Diaz O, Villafranca C, Ghezzo H, et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J. 2000;16(2):269–275.
   PubMed Web of Science ®Google Scholar
• Marin JM, Carrizo SJ, Gascon M, et al. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(6):1395–1399.
   PubMed Web of Science ®Google Scholar
• Pecchiari M, Radovanovic D, Santus P, et al. Airway occlusion assessed by single breath N2 test and lung P-V curve in healthy subjects and COPD patients. Respir Physiol Neurobiol. 2016;234:60–68. IV at the SBN2 test as the closing volume in COPD
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, Mascetti S, et al. Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD. Pharmacol Res. 2018;133:160–169.
   PubMedGoogle Scholar
• Santus P, Radovanovic D, Di Marco F, et al. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study. Pulm Pharmacol Ther. 2015;35:42–49.
   PubMed Web of Science ®Google Scholar
• Riley DJ, Liu RT, Edelman NH. Enhanced responses to aerosolized bronchodilator therapy in asthma using respiratory maneuvers. Chest. 1979;76(5):501–507.
   PubMedGoogle Scholar
• Baloira A, Abad A, Fuster A, et al. Lung deposition and inspiratory flow rate in patients with chronic obstructive pulmonary disease using different inhalation devices: a systematic literature review and expert opinion. Int J Chron Obstruct Pulmon Dis. 2021;16(1):1021–1033.
   PubMedGoogle Scholar
• Weers J. Suboptimal inspiratory flow rates with passive dry powder inhalers: big issue or overstated problem?. Front Drug Deliv. 2022;16(1):1021–1033
   Google Scholar